Log in to search using one of your social media accounts:

 

BRCA1 and BRCA2 mutation spectrum - an update on mutation distribution in a large cancer genetics clinic in Norway.
Conclusions: The spectrum of BRCA1 and BRCA2 mutations in the carrier population at Norway's largest cancer genetics clinic is diverse, and with a weaker founder effect than previously described. As a consequence, retesting the families that previously have been tested with specific tests/founder mutation tests should be a prioritised strategy to find more mutation positive families and possibly prevent cancer in healthy relatives. PMID: 29339979 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 18, 2018 Category: Cancer & Oncology Authors: Heramb C, Wangensteen T, Grindedal EM, Ariansen SL, Lothe S, Heimdal KR, Mæhle L Tags: Hered Cancer Clin Pract Source Type: research

Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer.
Abstract Purpose The 21-gene recurrence score (RS) breast cancer assay is clinically used to quantify risk of 10-year distant recurrence by category (low,
Source: Clinical Breast Cancer - January 17, 2018 Category: Cancer & Oncology Authors: Holowatyj AN, Cote ML, Ruterbusch JJ, Ghanem K, Schwartz AG, Vigneau FD, Gorski DH, Purrington KS Tags: J Clin Oncol Source Type: research

Epstein Barr virus and invasive mammary carcinomas: EBNA, EBERs and molecular profile in a population of West Algeria.
The objective of this study is to determine the association of EBV infection with infiltrating ductal carcinomas (IDC). This descriptive study was carried out in the laboratory of developmental biology and differentiation, from 2012 to 2014. Of 39 cases, we determined the clinicopathological characteristics of the population. Of the 23 cases of IDC, we implemented the techniques Elisa, immunohistochemistry and in situ hybridization. To determine the serological profile, overexpression of onco-proteins EBNA-1, HER2, the mitotic index Ki67 and detection of the presence of the viral genome. The mean age is 57.40±4, SBR...
Source: Clinical Breast Cancer - January 16, 2018 Category: Cancer & Oncology Authors: Yahia R, Zaoui C, Derbale W, Boudi H, Chebloune Y, Sahraoui T, Elkebir FZ Tags: Ann Biol Clin (Paris) Source Type: research

Inhibiting 6-phosphogluconate dehydrogenase selectively targets breast cancer through AMPK activation.
CONCLUSIONS: Our work provides experimental evidence on the association of 6PGD with poor prognosis in breast cancer and suggests that 6PGD inhibition may represent a potential therapeutic strategy to augment chemotherapy efficacy in breast cancer. PMID: 29340974 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 16, 2018 Category: Cancer & Oncology Authors: Yang X, Peng X, Huang J Tags: Clin Transl Oncol Source Type: research

Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years.
Conclusion No clinically significant differences were seen in overall QOL measured by the SF-36 summary measures and MENQOL between the letrozole and placebo groups. The data indicate that continuation of aromatase inhibitor therapy after 5 years of prior treatment in the trial population was not associated with a deterioration of overall QOL. PMID: 29328860 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 12, 2018 Category: Cancer & Oncology Authors: Lemieux J, Brundage MD, Parulekar WR, Goss PE, Ingle JN, Pritchard KI, Celano P, Muss H, Gralow J, Strasser-Weippl K, Whelan K, Tu D, Whelan TJ Tags: J Clin Oncol Source Type: research

Ticagrelor inhibits platelet-tumor cell interactions and metastasis in human and murine breast cancer.
We examined the potential of the reversible P2Y12 inhibitor ticagrelor, an agent used clinically to prevent cardiovascular and cerebrovascular events, to reduce tumor growth and metastasis. In vitro, MCF-7, MDA-MB-468, and MDA-MB-231 human mammary carcinoma cells exhibited decreased interaction with platelets treated with ticagrelor compared to untreated platelets. Prevention of tumor cell-platelet interactions through pretreatment of platelets with ticagrelor did not improve natural killer cell-mediated tumor cell killing of K562 myelogenous leukemia target cells. Additionally, ticagrelor had no effect on proliferation of...
Source: Clinical Breast Cancer - January 11, 2018 Category: Cancer & Oncology Authors: Gareau AJ, Brien C, Gebremeskel S, Liwski RS, Johnston B, Bezuhly M Tags: Clin Exp Metastasis Source Type: research

Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer.
Abstract During epithelial-mesenchymal transition (EMT) epithelial cancer cells trans-differentiate into highly-motile, invasive, mesenchymal-like cells giving rise to disseminating tumor cells. Only few of these disseminated cells successfully metastasize. Immune cells and inflammation in the tumor microenvironment was shown to drive EMT, but few studies investigated the consequences of EMT on tumor immunosurveillance. In addition to initiating metastasis, we demonstrate that EMT confers increased susceptibility to NK cells and contributes, in part, to the inefficiency of the metastatic process. Depletion of NK c...
Source: Clinical Breast Cancer - January 11, 2018 Category: Cancer & Oncology Authors: Chockley PJ, Chen J, Chen G, Beer DG, Standiford TJ, Keshamouni VG Tags: J Clin Invest Source Type: research

High nuclear MSK1 is associated with longer survival in breast cancer patients.
Abstract PURPOSE: Mitogen- and stress-activated kinases (MSKs) are important substrates of the mitogen-activated protein kinase (MAPK)-activated protein kinase family. MSK1 and MSK2 are both nuclear serine/threonine protein kinases, with MSK1 being suggested to potentially play a role in breast cancer cell proliferation, cell cycle progression, cell migration, invasion and tumour growth. The aim of the current study was to assess MSK1 protein expression in breast cancer tumour specimens, evaluating its prognostic significance. METHODS: A large cohort of 1902 early stage invasive breast cancer patients was use...
Source: Clinical Breast Cancer - January 11, 2018 Category: Cancer & Oncology Authors: Pu X, Storr SJ, Ahmad NS, Rakha EA, Green AR, Ellis IO, Martin SG Tags: J Cancer Res Clin Oncol Source Type: research

Systemic therapy for brain metastases.
Abstract Central nervous system metastases cause grave morbidity in patients with advanced malignancies. Lung cancer, breast cancer, and melanoma are the three most common causes of brain metastases. Although the exact incidence of brain metastases is unclear, there appears to be an increasing incidence which has been attributed to longer survival, better control of systemic disease, and better imaging modalities. Until recently surgical resection of solitary or symptomatic brain metastases, and radiation therapy (either whole-brain radiation therapy or stereotactic radiation) were the mainstay of treatment for pa...
Source: Clinical Breast Cancer - January 10, 2018 Category: Cancer & Oncology Authors: Venur VA, Karivedu V, Ahluwalia MS Tags: Handb Clin Neurol Source Type: research

Leptomeningeal metastasis.
Abstract Leptomeningeal metastasis (LM) results from dissemination of cancer cells to both the leptomeninges (pia and arachnoid) and cerebrospinal fluid (CSF) compartment. Breast cancer, lung cancer, and melanoma are the most common solid tumors that cause LM. Recent approval of more active anticancer therapies has resulted in improvement in survival that is partly responsible for an increased incidence of LM. Neurologic deficits, once manifest, are mostly irreversible, and often have a significant impact on patient quality of life. LM-directed therapy is based on symptom palliation, circumscribed use of neurosurg...
Source: Clinical Breast Cancer - January 10, 2018 Category: Cancer & Oncology Authors: Taillibert S, Chamberlain MC Tags: Handb Clin Neurol Source Type: research

Brain metastases: epidemiology.
Abstract Brain metastases (BM) are the most commonly diagnosed type of central nervous system tumor in the United States. Estimates of the frequency of BM vary significantly, as there is no nationwide reporting system for metastases. BM may be the first sign of a previously undiagnosed cancer, or occur years or decades after the primary cancer was diagnosed. Incidence of BM varies significantly by primary cancer site. Lung, breast, and melanoma continue to be the leading cause of BM. These tumors are increasingly more common as new therapeutics, advanced imaging, and improved screening have led to lengthened survi...
Source: Clinical Breast Cancer - January 10, 2018 Category: Cancer & Oncology Authors: Ostrom QT, Wright CH, Barnholtz-Sloan JS Tags: Handb Clin Neurol Source Type: research

Metastatic diseases of the central nervous system - neuropathologic aspects.
Abstract A large percentage of patients with cancer will develop brain metastases, and many of them will die within a few months following diagnosis of intracranial metastasis. Although the majority of the central nervous system metastases are derived from a well-known primary neoplasm, about 5-10% of brain metastases are from an unknown source, making the tissue diagnosis a first step in the search for a primary malignancy. The pathologist utilizes several immunohistochemical and molecular diagnostic tools for such investigation, helping the clinical oncologist to narrow down the clinical and radiologic explorati...
Source: Clinical Breast Cancer - January 10, 2018 Category: Cancer & Oncology Authors: Lopes MBS Tags: Handb Clin Neurol Source Type: research

Evaluation of a 27-gene inherited cancer panel across 630 consecutive patients referred for testing in a clinical diagnostic laboratory.
Conclusion: These results provide the actual percentage of family or personal history of cancer that can be attributed to pathogenic or likely pathogenic variants in one or more of the genes on our panel and corroborate the utility of multi-gene panels over sequential testing to identify individuals with an inherited predisposition to cancer. PMID: 29308099 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 10, 2018 Category: Cancer & Oncology Authors: Gardner SA, Weymouth KS, Kelly WS, Bogdanova E, Chen W, Lupu D, Suhl J, Zeng Q, Geigenmüller U, Boles D, Okamoto PM, McDowell G, Hayden MA, Nagan N Tags: Hered Cancer Clin Pract Source Type: research

Indoor Tanning a Gianus Bifrons: Vitamin D and Human Cancer.
Abstract Despite it is now undeniable that indoor tanning exposure is associated with a number of skin cancers, its favorable effects on vitamin D status may bear some underestimated and currently unexplored health benefits. Vitamin D is a fat-soluble vitamin naturally present in a limited number of foods, the concentration of which largely depends on ultraviolet (UV) B sources exposure in humans. A strong, graded, and inverse association has been documented between serum vitamin D and the risk of developing certain types of malignancy, especially colorectal, breast, lung, bladder, and kidney cancers. The overall ...
Source: Clinical Breast Cancer - January 8, 2018 Category: Cancer & Oncology Authors: Lippi G, Cervellin G, Danese E Tags: Adv Clin Chem Source Type: research

Locked Nucleic Acid Technology for Highly Sensitive Detection of Somatic Mutations in Cancer.
Abstract The molecular diagnosis of the cancer mutational status is essential for modern clinical laboratory medicine. Mutations in EGFR, KRAS, BRAF, and PIK3CA genes are widely analyzed in solid tumors such as lung cancer, colorectal cancer, breast cancer, and melanoma. The allele-specific polymerase chain reaction, high-resolution melting, and Sanger sequencing are used for detecting and identifying gene mutations in many clinical laboratories. The locked nucleic acid (LNA) is a class of nucleic acid analogs that contain a methylene bridge connecting the 2' oxygen and 4' carbon in the ribose moiety. This methyle...
Source: Clinical Breast Cancer - January 8, 2018 Category: Cancer & Oncology Authors: Ishige T, Itoga S, Matsushita K Tags: Adv Clin Chem Source Type: research

GSTP1 methylation in cancer: a liquid biopsy biomarker?
Abstract The coding region of GSTP1 gene is preceded by a large CpG-rich region that is frequently affected by methylation. In many cancer types, GSTP1 is affected by hypermethylation and, as a consequence, it has a low expression. The aim of this review is to give an overview on GSTP1 methylation studies with a special focus on liquid biopsy, thus to summarize methods, results, sample types, different diseases, to have a complete information regarding this promising epigenetic biomarker. We used all the most valuable scientific search engines (PubMed, Medline, Scopus and Web of Science) searching the following ke...
Source: Clinical Breast Cancer - January 6, 2018 Category: Cancer & Oncology Authors: Gurioli G, Martignano F, Salvi S, Costantini M, Gunelli R, Casadio V Tags: Clin Chem Lab Med Source Type: research

Influence of physical activity on the immune system in breast cancer patients during chemotherapy.
CONCLUSION: Chemotherapy led to a decrease in nearly all measured immune cells. In this study, physical intervention with endurance or resistance training did not suppress cellular immunity any further. Larger multicenter trials are needed to evaluate the exact impact of sports intervention on immune cell subpopulations. PMID: 29305709 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 5, 2018 Category: Cancer & Oncology Authors: Schmidt T, Jonat W, Wesch D, Oberg HH, Adam-Klages S, Keller L, Röcken C, Mundhenke C Tags: J Cancer Res Clin Oncol Source Type: research

Isolated breast metastasis from gastric cancer in a male patient.
Abstract A 72-year-old man underwent total gastrectomy for gastric cancer (por2, T3, N2, Stage IIIA). Eleven courses of postoperative chemotherapy with TS-1 (tegafur/gimeracil/oteracil) were administered. Five months after surgery, the serum carcinoembryonic antigen value was slightly elevated. However, computed tomography did not reveal any metastatic lesions in other organs. Two years after surgery, the patient felt a mass in the left mammary. A 2-cm tumor was palpable in the central portion of the breast. Ultrasonography revealed a hypoechoic tumor, which was Class 3 on aspiration biopsy cytological examination...
Source: Clinical Breast Cancer - January 4, 2018 Category: Cancer & Oncology Authors: Kubo H, Shimizu T, Sekido H, Matsuda G, Takeda K, Watanabe A, Sakamoto R, Yamamoto Y, Toyoda J, Niino H Tags: Clin J Gastroenterol Source Type: research

Risk factors for unplanned discontinuation of scheduled treatment in elderly patients with castration-resistant prostate cancer: results of the IBuTu study.
ch L Abstract PURPOSE: To gain knowledge about the factors associated with discontinuation of scheduled treatment in elderly men with castration-resistant prostate cancer (CRPC). METHODS: Patients ≥ 70 years with CRPC starting a new line of treatment were included in a prospective cohort study. A geriatric assessment (CGA) was performed at baseline, including comorbidity, mobility, functional/mental/nutritional status, as well as depression. Furthermore, pain intensity, quality of life, ECOG-performance status, and physicians' and patients' perception of health were documented. Reasons f...
Source: Clinical Breast Cancer - January 4, 2018 Category: Cancer & Oncology Authors: Honecker F, Wedding U, Kallischnigg G, Schroeder A, Klier J, Frangenheim T, Weißbach L Tags: J Cancer Res Clin Oncol Source Type: research

Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.
Abstract Purpose Cell-free DNA (cfDNA) offers the potential for minimally invasive genome-wide profiling of tumor alterations without tumor biopsy and may be associated with patient prognosis. Triple-negative breast cancer (TNBC) is characterized by few mutations but extensive somatic copy number alterations (SCNAs), yet little is known regarding SCNAs in metastatic TNBC. We sought to evaluate SCNAs in metastatic TNBC exclusively via cfDNA and determine if cfDNA tumor fraction is associated with overall survival in metastatic TNBC. Patients and Methods In this retrospective cohort study, we identified 164 patients...
Source: Clinical Breast Cancer - January 3, 2018 Category: Cancer & Oncology Authors: Stover DG, Parsons HA, Ha G, Freeman SS, Barry WT, Guo H, Choudhury AD, Gydush G, Reed SC, Rhoades J, Rotem D, Hughes ME, Dillon DA, Partridge AH, Wagle N, Krop IE, Getz G, Golub TR, Love JC, Winer EP, Tolaney SM, Lin NU, Adalsteinsson VA Tags: J Clin Oncol Source Type: research

Circulating Tumor DNA Guides Prognosis in Metastatic Triple-Negative Breast Cancer.
PMID: 29298118 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 3, 2018 Category: Cancer & Oncology Authors: Zivanovic Bujak A, Dawson SJ Tags: J Clin Oncol Source Type: research

Descriptions of Fundamental Care needs in cancer care - an exploratory study.
CONCLUSION: Some people with a cancer diagnosis have to strive for help and support from the nursing staff to manage to regain control over their recovery. Nurses in cancer care need to focus on the patients' fundamental care needs to optimise their patients' recovery. This article is protected by copyright. All rights reserved. PMID: 29292542 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 2, 2018 Category: Cancer & Oncology Authors: Muntlin Athlin Å, Browall M, Wengström Y, Conroy T, Kitson AL Tags: J Clin Nurs Source Type: research

Reply to E. Ramos et al.
PMID: 29293390 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 2, 2018 Category: Cancer & Oncology Authors: Hughes KS Tags: J Clin Oncol Source Type: research

No association between the risk of breast cancer and systemic lupus erythematosus: evidence from a meta-analysis.
Abstract Several studies have estimated breast cancer risk in patients with systemic lupus erythematosus (SLE) relative to the general population. However, the results have been inconclusive. Therefore, we conducted a meta-analysis to ascertain a more comprehensive conclusion. A systematic literature search of electronic databases including PubMed, Web of Science, Embase, Cochrane Library, and Scopus was conducted to identify eligible studies using multiple search strategies. Based on the degree of heterogeneity, a random-effect model was chosen to calculate the pooled standardized incidence rate (SIR) with 95% co...
Source: Clinical Breast Cancer - January 2, 2018 Category: Cancer & Oncology Authors: Rezaieyazdi Z, Tabaei S, Ravanshad Y, Akhtari J, Mehrad-Majd H Tags: Clin Rheumatol Source Type: research

Correction to: Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of Primary Care Physicians (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), Spanish Society for General and Family Physicians (SEMG), Spanish Society of Obstetrics and Gynecology (SEGO), Spanish Society of Radiation Oncology (SEOR), Spanish Society of Senology and Breast Pathology (SESPM), and Spanish Society of Cardiology (SEC).
dez T Abstract Correction to: Clin Transl Oncol https://doi.org/10.1007/s12094-017-1801-4. PMID: 29294225 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 2, 2018 Category: Cancer & Oncology Authors: Barnadas A, Algara M, Cordoba O, Casas A, Gonzalez M, Marzo M, Montero A, Muñoz M, Ruiz A, Santolaya F, Fernandez T Tags: Clin Transl Oncol Source Type: research

Considerations in Testing for Inherited Breast Cancer Predisposition in the Era of Personalized Medicine.
This article provides an overview of individuals at risk for inherited cancer predisposition and recommendations for surveillance and management. PMID: 29132555 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Powers B, Pal T, Laronga C Tags: Surg Oncol Clin N Am Source Type: research

Neoadjuvant Endocrine Therapy: Who Benefits Most?
Abstract Neoadjuvant endocrine therapy (NET) can be effective at downstaging patients with estrogen receptor-positive tumors and identifying those tumors that are endocrine sensitive and resistant. The optimal prognostic markers for stratification are under investigation. Use of NET will allow the identification of patients with estrogen receptor-positive tumors who might benefit from additional treatment and allow better understanding of endocrine resistance. PMID: 29132556 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Grossman J, Ma C, Aft R Tags: Surg Oncol Clin N Am Source Type: research

Triple-Negative Breast Cancer: Who Should Receive Neoadjuvant Chemotherapy?
Abstract Progress in the treatment of triple-negative breast cancer remains an important challenge. Given the aggressive biology and high risk of distant recurrence, systemic chemotherapy is warranted in most patients. Neaodjuvant chemotherapy benefits patients with locally advanced disease by downsizing the tumor and increasing the probability of breast-conserving surgery. Clinical and pathologic responses provide important prognostic information, which makes neoadjuvant therapy an attractive approach for all patients with triple-negative breast cancer. Clinical research in the neoadjuvant setting is focused on i...
Source: Clinical Breast Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Chaudhary LN, Wilkinson KH, Kong A Tags: Surg Oncol Clin N Am Source Type: research

Intraoperative Margin Assessment in Breast Cancer Management.
Abstract The goal of breast-conserving surgery is to excise the tumor with negative margins while achieving a successful cosmetic result. Although it is not feasible to have re-excision rates of zero, several techniques have been described to reduce the need for a return to the operating room. When rates of re-excision are high, consideration should be given to using 1 or more of these techniques. It is critical that re-excision rates are tracked when new techniques are implemented to ensure progress. In addition, attention must be paid to ensuring that cosmetic outcomes remain optimal. PMID: 29132558 [PubMed...
Source: Clinical Breast Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Reyna C, DeSnyder SM Tags: Surg Oncol Clin N Am Source Type: research

Oncoplastic Breast Reconstruction: Should All Patients be Considered?
Abstract Oncoplastic surgery of the tissue defect from partial mastectomy should be considered for all patients. It can result in in significant asymmetries from scar contraction, skin tethering, and alterations in the nipple areolar complex location. Indications, risks, and benefits are discussed. Optimal procedures are described, considering resected specimen volume, primary tumor location, tumor to breast size ratio, and the impact on the nipple areolar complex. Indications for plastic surgery consultation and joint surgery are discussed. Surgical management includes incision planning, preservation of the nippl...
Source: Clinical Breast Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Habibi M, Broderick KP, Sebai ME, Jacobs LK Tags: Surg Oncol Clin N Am Source Type: research

Alternatives to Standard Fractionation Radiation Therapy After Lumpectomy: Hypofractionated Whole-Breast Irradiation and Accelerated Partial-Breast Irradiation.
Abstract Adjuvant whole-breast irradiation (WBI) after lumpectomy has been an established standard of care for decades. Standard-fractionation WBI delivered over 5 to 7 weeks can achieve durable tumor control with low toxicity but can be inconvenient for patients and cost ineffective. Hypofractionated WBI can be completed in 3 to 4 weeks and, based on long-term randomized data, is the preferred standard of care in select patients. Accelerated partial-breast irradiation can be delivered using even shorter treatment regimens. Although the available data on accelerated partial-breast irradiation is more lim...
Source: Clinical Breast Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Ohri N, Haffty BG Tags: Surg Oncol Clin N Am Source Type: research

Breast Cancer Disparities: How Can We Leverage Genomics to Improve Outcomes?
Abstract Breast cancer mortality rates are higher in African American compared with white American women. Disproportionately rising incidence rates, coupled with higher rates of biologically aggressive disease among African Americans is resulting in a widening of the mortality disparity. Higher rates of triple-negative breast cancer among African American women, as well as women from western sub-Saharan Africa, has prompted questions regarding the role of African ancestry as a marker of hereditary susceptibility for specific disease phenotypes. Advances in germline genetics, as well as somatic tumor genomic resear...
Source: Clinical Breast Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Davis MB, Newman LA Tags: Surg Oncol Clin N Am Source Type: research

When Does Atypical Ductal Hyperplasia Require Surgical Excision?
Abstract Atypical ductal hyperplasia (ADH) is a proliferative, nonobligate precursor breast lesion and a marker of increased risk for breast carcinoma. Surgical excision remains the standard recommendation following a core needle biopsy result consistent with ADH. Recent research suggests that women with no mass lesion or discordance, removal of greater than or equal to 90% of calcifications at the time of core needle biopsy, involvement of less than or equal to 2 terminal duct lobular units, and absence of cytologic atypia or necrosis are likely to have a less than 5% chance of a missed cancer. PMID: 2913256...
Source: Clinical Breast Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Racz JM, Degnim AC Tags: Surg Oncol Clin N Am Source Type: research

Tomosynthesis in Breast Cancer Imaging: How Does It Fit into Preoperative Evaluation and Surveillance?
Abstract An important limitation of conventional two-dimensional mammography is the overlap of dense breast tissue obscuring masses. Digital breast tomosynthesis (DBT) has emerged as a mammographic technology that overcomes this limitation and is considered an overall better mammogram. DBT has been shown to detect significantly more breast cancer than conventional two-dimensional mammography, and to decrease the number of callbacks for diagnostic evaluation from screening mammography. Usually the callback evaluation is deemed to be overlap of tissue requiring no further management. DBT is used in the screening and...
Source: Clinical Breast Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Eghtedari M, Tsai C, Robles J, Blair SL, Ojeda-Fournier H Tags: Surg Oncol Clin N Am Source Type: research

Anatomy and Breast Cancer Staging: Is It Still Relevant?
Abstract Breast cancer staging concisely summarizes disease status, creating a framework for assessing and relaying prognostic information. The fundamental concepts and components of breast cancer staging are reviewed. The AJCC Cancer Staging Manual, which includes traditional anatomic factors, now includes additional tumor characteristics: tumor grade, estrogen receptor status, progesterone receptor status, human epidermal growth factor receptor 2 status, and (when available) multigene panel testing from the primary tumor. With these updates, staging provides the most reliable system for accurately predicting pat...
Source: Clinical Breast Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Plichta JK, Campbell BM, Mittendorf EA, Hwang ES Tags: Surg Oncol Clin N Am Source Type: research

Are There Alternative Strategies for the Local Management of Ductal Carcinoma in Situ?
Abstract The management of ductal carcinoma in situ (DCIS) has traditionally followed the evidence base for invasive breast cancer using surgery, radiation therapy, and drug therapy to remove the DCIS from the breast and reduce the risk of recurrence for both DCIS and invasive breast cancer. Because of concerns regarding the overtreatment of DCIS, randomized controlled trials have been established to test the outcomes (invasive breast cancer outcomes and patient-reported outcome measures) of active surveillance compared with guideline-concordant care for low-risk (for progression) DCIS. These strategies are u...
Source: Clinical Breast Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Rosso KJ, Weiss A, Thompson AM Tags: Surg Oncol Clin N Am Source Type: research

Lobular Breast Cancer: Different Disease, Different Algorithms?
Abstract Invasive lobular carcinoma (ILC) is the second most common type of breast cancer, with a unique pathogenesis and distinct clinical biology. ILCs display a characteristic loss of E-cadherin, are largely estrogen receptor positive, HER2 negative, and low to intermediate grade. These features portend a favorable prognosis, but there is a tendency for late recurrences and atypical metastases. ILCs tend to be insidious and infiltrative, which can pose a challenge for diagnosis, and emerging data suggest they may have a propensity for a differing response to standard therapies. PMID: 29132567 [PubMed - in ...
Source: Clinical Breast Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Mamtani A, King TA Tags: Surg Oncol Clin N Am Source Type: research

Innovation in the Diagnosis and Management of Breast Cancer.
PMID: 29132569 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Pawlik TM Tags: Surg Oncol Clin N Am Source Type: research

Integrating New Knowledge and Surgical Innovation into the Diagnosis and Management of Breast Cancer.
PMID: 29132570 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Hunt KK Tags: Surg Oncol Clin N Am Source Type: research

Modern Approaches to the Surgical Management of Malignant Breast Disease: The Role of Breast Conservation, Complete Mastectomy, Skin- and Nipple-Sparing Mastectomy.
This article provides an overview of these modern surgical approaches for breast cancer treatment. PMID: 29080650 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 1, 2017 Category: Cancer & Oncology Authors: Cil TD, McCready D Tags: Clin Plast Surg Source Type: research

Indications and Controversies in Lipofilling for Partial Breast Reconstruction.
Abstract The treatment of sequelae after conservative breast cancer treatment can be a challenge. Lipomodeling, although controversial in the beginning, is a safe technique that can help in the treatment of these deformities, without an important impact on the imaging surveillance. Depending on the severity of the deformity, one or several sessions of fat transfer can be required. The technique is easy and reproducible, but before obtaining satisfying results with a low complication rate, a learning curve should be completed. The final result is natural, with normal breast consistency, with no additional scars. ...
Source: Clinical Breast Cancer - November 1, 2017 Category: Cancer & Oncology Authors: Delay E, Guerid S, Meruta AC Tags: Clin Plast Surg Source Type: research

Risk-Reducing Mastectomy and Breast Reconstruction: Indications and Evidence for Current Management Strategies.
Abstract Breast cancer affects nearly every woman either personally or through a family member or friend. Awareness of associated familial and genetic risks has been steadily increasing over the last decade. Bilateral risk-reduction mastectomy seeks to decrease the incidence and mortality of breast cancer in women without abnormality but with elevated risk of developing cancer. Contralateral risk-reduction mastectomy aims to decrease the incidence of contralateral breast cancer in women diagnosed with unilateral breast cancer. As understanding improves and techniques progress, the relative merits of surgical risk ...
Source: Clinical Breast Cancer - November 1, 2017 Category: Cancer & Oncology Authors: Eisemann BS, Spiegel AJ Tags: Clin Plast Surg Source Type: research

Patient-Centered Breast Reconstruction Based on Health-Related Quality-of-Life Evidence.
Abstract The article summarizes the available evidence regarding clinical decision making in breast reconstruction from the patient perspective of satisfaction and health-related quality of life. A review of generic and specific patient reported outcome measures is provided. Important components of breast reconstruction care are compared, such as timing of reconstruction, autologous and implant-based reconstruction, and the use of nipple-sparing and skin-sparing mastectomy. This evidence-based summary will be useful to guide clinicians when discussing breast reconstruction with their patients. PMID: 29080656 ...
Source: Clinical Breast Cancer - November 1, 2017 Category: Cancer & Oncology Authors: Platt J, Zhong T Tags: Clin Plast Surg Source Type: research

Neoadjuvant Chemotherapy for Breast Cancer Treatment and the Evidence-Based Interaction with Immediate Autologous and Implant-Based Breast Reconstruction.
This article aims to determine the impact of neoadjuvant chemotherapy on immediate breast reconstruction by assessing their compatibility for oncological safety and the incidence and management of postoperative complications. A review of scientific publications published between 2009 and 2017 was undertaken. The relationship between neoadjuvant chemotherapy and immediate breast reconstruction was analyzed to compile and assess the potential interaction between the procedures. The search was limited to English language publications, but there were no limiting factors at the level of study typology. Full-text articles, inclu...
Source: Clinical Breast Cancer - November 1, 2017 Category: Cancer & Oncology Authors: Riba J, de Romani SE, Masia J Tags: Clin Plast Surg Source Type: research

Indications and Controversies in Partial Mastectomy Defect Reconstruction.
This article describes the authors' many years of experience of breast cancer treatment using oncoplastic surgery. They also established a decision-making guide, whose implementation enables treatment of every patient. PMID: 29080658 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 1, 2017 Category: Cancer & Oncology Authors: Honart JF, Reguesse AS, Struk S, Sarfati B, Rimareix F, Alkhashnam H, Kolb F, Rem K, Leymarie N Tags: Clin Plast Surg Source Type: research

Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer.
Conclusions: In this study, we were able to show that the newly designed questionnaire is a useful tool for evaluating cancer family history along with Society of Gynecologic Oncology criteria or Amsterdam criteria II. When considering the risk of Lynch syndrome for a patient with ovarian cancer, it is important to collect a second and third relative's family history. PMID: 28334914 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 24, 2017 Category: Cancer & Oncology Authors: Masuda K, Hirasawa A, Irie-Kunitomi H, Akahane T, Ueki A, Kobayashi Y, Yamagami W, Nomura H, Kataoka F, Tominaga E, Banno K, Susumu N, Aoki D Tags: Jpn J Clin Oncol Source Type: research

The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes.
Abstract BACKGROUND: The targeted ERBB2 therapy, trastuzumab, has had a tremendous impact on management of patients with HER2+ breast cancer, leading to development and increased use of further HER2 targeted therapies. The major clinical side effect is cardiotoxicity but the mechanism is largely unknown. On the basis that gene expression is known to be altered in multiple models of heart failure, we examined differential gene expression of iPSC-derived cardiomyocytes treated at day 11 with the ERBB2 targeted monoclonal antibody, trastuzumab for 48 h and the small molecule tyrosine kinase inhibitor of EGFR and...
Source: Clinical Breast Cancer - January 21, 2017 Category: Cancer & Oncology Authors: Necela BM, Axenfeld BC, Serie DJ, Kachergus JM, Perez EA, Thompson EA, Norton N Tags: Clin Transl Med Source Type: research

Final report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japan.
CONCLUSIONS: The survival results in this study are in line with those of previously reported, reliable, studies. The safety and tolerability of the protocol regimen have already been confirmed. Oral capecitabine is acceptable as adjuvant chemotherapy for Japanese patients with resected stage III colon cancer. PMID: 28101757 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 17, 2017 Category: Cancer & Oncology Authors: Minami K, Morita M, Emi Y, Okamoto M, Tanaka E, Nagata S, Touyama T, Ohgaki K, Tanaka T, Okumura H, Suenaga T, Tokunaga S, Oki E, Kakeji Y, Akagi Y, Baba H, Natsugoe S, Maehara Y, Kyushu Study Group of Clinical Cancer (KSCC) Tags: Int J Clin Oncol Source Type: research

Mammary Gland Involution Provides a Unique Model to Study the TGF- β Cancer Paradox.
This article reviews facets of mammary gland involution that are TGF-β regulated, namely mammary epithelial cell death, immune activation, and extracellular matrix remodeling. We outline how distinct cellular responses and crosstalk between cell types during physiologically normal mammary gland involution contribute to simultaneous tumor suppressive and promotional microenvironments. We also highlight alternatives to direct TGF-β blocking anti-cancer therapies with an emphasis on eliciting concerted microenvironmental-mediated tumor suppression. PMID: 28098775 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 12, 2017 Category: Cancer & Oncology Authors: Guo Q, Betts C, Pennock N, Mitchell E, Schedin P Tags: J Clin Med Source Type: research

The outcomes of radiotherapy and factors that predict overall survival in elderly patients with esophageal squamous cell carcinoma.
CONCLUSION: Radiation therapy in elderly patients (≥70 years) can not only obtain good treatment result, but also make patients have better tolerance and reduce the risk of complications. Radiotherapy should be as a primary treatment option for elderly patients with inoperable ESCC. PMID: 28091898 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 12, 2017 Category: Cancer & Oncology Authors: Yin H, E M, Zhang H, Wang C Tags: Clin Transl Oncol Source Type: research